AMG 714 Expanded Access Program

A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects

NCT02703051 ·Status: COMPLETED ·Phase: PHASE1

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04225871 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

NCT04980495 ·Status: COMPLETED ·Phase: PHASE3

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

NCT06298565 ·Status: RECRUITING

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

NCT05681715 ·Status: COMPLETED ·Phase: PHASE3

Treatment of IgG4-Related Disease With Revlimid and Rituximab

NCT02705638 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

NCT00727194 ·Status: TERMINATED ·Phase: PHASE2

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

NCT00385697 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)

NCT02774239 ·Status: COMPLETED ·Phase: PHASE3

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

NCT06456580 ·Status: RECRUITING ·Phase: PHASE3

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

NCT02334306 ·Status: COMPLETED ·Phase: PHASE2

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

NCT04833894 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

NCT05136976 ·Status: RECRUITING ·Phase: PHASE3

Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)

NCT02725476 ·Status: COMPLETED ·Phase: PHASE2

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

NCT03863080 ·Status: COMPLETED ·Phase: PHASE2

Myasthenia Gravis Foundation of America Global MG Patient Registry

NCT06617741 ·Status: RECRUITING

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

NCT04450654 ·Status: WITHDRAWN ·Phase: PHASE2

Zilucoplan for Severe gMG Exacerbations

NCT07215949 ·Status: RECRUITING ·Phase: PHASE3

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

NCT01906372 ·Status: COMPLETED ·Phase: PHASE2

The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis

NCT06958939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

NCT06765161 ·Status: RECRUITING ·Phase: PHASE3

Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis

NCT00774462 ·Status: COMPLETED ·Phase: PHASE2

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases

NCT07284797 ·Status: RECRUITING ·Phase: PHASE1